Warning Letters Special Report: Pandemic Drove Focused Inspections, Alternative Approaches

In the first part of our in-depth series, the Pink Sheet outlines how 2022 warning letters reflected agency’s efforts to overcome COVID-19 travel restrictions. As pandemic abates, a new, less inspection-intensive normal could emerge.

Warning Letters Special Report
How the FDA found so many problems with so few inspections • Source: Shutterstock

Two factors enabled the US Food and Drug Administration to continue pressing the pharmaceutical industry on quality with warning letters in 2021 and 2022 even after the COVID-19 pandemic largely grounded its inspectorate, according to agency data analyzed by the Pink Sheet.

One: The agency became more selective with the drug good manufacturing practice inspections it was able to conduct.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance